Trial Profile
A Phase 2 Study of Orally Administered PLX3397 in Patients With Recurrent Glioblastoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Pexidartinib (Primary)
- Indications Glioblastoma
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Daiichi Sankyo Company; Plexxikon
- 06 Jan 2020 Status changed from completed to discontinued.
- 26 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 09 Dec 2014 Planned End Date changed from 1 Sep 2013 to 1 Jan 2015 as reported by ClinicalTrials.gov record.